Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the women's health initiative observational study

JAMA

Volumn 288, Issue 8, 2002, Pages 980-987

  Pradhan, Aruna D ^a   Manson, Joann E ^a   Rossouw, Jacques E ^b   Siscovick, David S ^c   Mouton, Charles P ^d   Rifai, Nader ^a   Wallace, Robert B ^e   Jackson, Rebecca D ^f   Pettinger, Mary B ^g   Ridker, Paul M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; SEX HORMONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG USE; FEMALE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 0037190065     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.8.980     Document Type: Article

References (38)

1. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
2. Hormone replacement therapy and increased plasma concentration of C-reactive protein
3. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
4. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
5. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
6. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly
7. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA Augsburg Cohort Study, 1984 to 1992
8. Novel risk factors for systemic atherosclerosis
9. Low grade inflammation and coronary heart disease
10. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
11. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
12. Risks and benefits of estrogen plus progestin in healthy postmenopausal women
13. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
14. Design of the Women's Health Initiative clinical trial and observational study
15. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo
16. C-reactive protein in healthy subjects
17. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women
18. Obesity and cardiovascular disease
19. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene
20. Production of C-reactive protein and risk of coronary events in stable and unstable angina
21. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
22. Creactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes
23. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
24. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group
25. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
26. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
27. Impact of postmenopausal hormone therapy on cardiovascular events and cancer
28. Hormone replacement therapy, inflammation, and hemostasis in elderly women
29. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
30. The effects of hormone replacement therapy and raloxifene on Creactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
31. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women
32. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
33. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein
34. Interferongamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein
35. Long-term effects of pravastatin on plasma concentration of C-reactive protein
36. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
37. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events